Lialda Shortage: What Providers and Prescribers Need to Know in 2026

As a provider managing patients with ulcerative colitis, you may have fielded calls from patients who cannot fill their Lialda (mesalamine 1.2 g delayed-release tablets) prescription. Understanding the access landscape in 2026 is critical for maintaining treatment continuity and avoiding preventable UC flares in your patients.

This briefing covers current availability, clinical considerations, prescribing strategies, formulary landscape, and patient-facing tools that can streamline medication access.

Current Supply Status (2026)

As of Q1 2026, neither brand-name Lialda nor generic mesalamine 1.2 g delayed-release tablets appear on the FDA's active drug shortage list. Multiple generics manufacturers — including Zydus Pharmaceuticals and Camber Pharmaceuticals — produce the 1.2 g delayed-release tablet, providing redundancy in the supply chain.

Note: Mesalamine 500 mg extended-release capsules (the Pentasa/Apriso formulation class) have had documented shortage issues in 2025-2026 — specifically Sun Pharma's 500 mg ER product, reported as back-ordered by ASHP as of March 2026. This is a distinct formulation from Lialda's delayed-release tablets and should not be conflated with Lialda availability.

The practical access landscape tells a more nuanced story, however. Patient-reported access challenges persist for several reasons:

• Generic transition: Major retail chains have largely discontinued brand-name Lialda from their standard inventory in favor of generic mesalamine DR. Brand-specific prescriptions may not be fillable same-day at many chains.
• Automated inventory: Chain pharmacy ordering algorithms allocate stock based on dispensing volume. Pharmacies with low GI patient populations may deprioritize mesalamine stocking.
• Insurance formulary restrictions: Many commercial plans place brand Lialda on Tier 3 or higher and require step therapy or prior authorization. The administrative burden can delay access significantly.

Clinical Implications for Prescribers

Medication access disruptions are a significant adherence risk for UC patients on mesalamine maintenance therapy. Research shows non-compliant mesalamine patients have a five-fold greater risk of disease flares. The once-daily dosing design of Lialda was explicitly intended to improve compliance — but local pharmacy availability now undermines that clinical benefit.

Prescribing Strategies to Improve Access

Several prescribing adjustments can reduce the likelihood of access problems:

• Prescribe generic mesalamine DR by formulation, not brand name. Write "mesalamine 1.2 g delayed-release tablets" (DAW-0) rather than "Lialda." This significantly broadens pharmacy availability and reduces insurance barriers.
• Prescribe 90-day supplies when appropriate. For stable maintenance patients, a 90-day supply through mail order reduces the frequency of access problems and supports better adherence.
• Check formulary status before prescribing. Use your EHR's formulary check tool or call the patient's insurance to confirm mesalamine DR is covered and identify any step therapy requirements.
• Have an alternative ready. If a patient cannot access mesalamine DR, have a clinical plan for bridging — whether that's a rectal mesalamine product for distal disease, an alternative 5-ASA (Delzicol, Asacol HD), or a short course of corticosteroids if needed.

Understanding the Mesalamine Formulation Landscape

Not all mesalamine products are interchangeable. Ensure your team and patients understand these distinctions:

• Lialda / generic mesalamine 1.2 g DR tablets: MMX technology, once daily, induction (2.4–4.8 g/day) and maintenance (2.4 g/day), approved for adults and pediatric patients ≥5 years/≥24 kg, take WITH food
• Apriso / generic mesalamine 0.375 g ER capsules: Intellicor technology, once daily (1.5 g/day), maintenance only, adults only, can be taken without food
• Delzicol / generic mesalamine 400 mg DR capsules: Multiple daily doses, induction and maintenance, adults and pediatrics 5+
• Pentasa / generic mesalamine 250–500 mg ER capsules: Releases throughout entire GI tract, multiple daily doses, useful for proximal disease involvement. Note: 500 mg ER generic has experienced shortage (Sun Pharma back-order, 2026).

Cost and Coverage Considerations for Your Patients

Brand Lialda carries a retail price of over $1,100 for a 30-day supply (120 tablets at 4 tablets/day). Generic mesalamine 1.2 g DR is the cost-effective and clinically equivalent option:

• Retail price for generic: approximately $389 for 120 tablets
• With GoodRx coupon: as low as $45 per fill
• With SingleCare coupon: as low as $74-$109 per fill
• Insurance: typically Tier 1–2 for generic; prior auth/step therapy may apply for brand

For uninsured or underinsured patients, the Takeda Patient Assistance Program may provide access to brand Lialda at low or no cost for eligible patients. NeedyMeds.org is also a useful resource for your team to share with patients.

Tools to Help Your Patients Find Lialda

medfinder offers real-time pharmacy availability data that can help your clinical team identify which pharmacies currently have mesalamine in stock. Patients can use medfinder's provider tools to quickly locate their medication without calling multiple pharmacies. This is particularly useful for patients in areas with limited pharmacy access or those who are already managing a flare.

Clinical Bottom Line

Lialda is not in formal shortage in 2026, but the access landscape requires proactive management. Prescribing generic mesalamine DR by formulation, planning for 90-day fills, and equipping patients with pharmacy-finding tools can eliminate most access-related treatment interruptions. See our companion guide: How to help your patients find Lialda in stock: A provider's guide